Section Arrow
NRXP.NASDAQ
- NRX Pharmaceuticals
(Financial Status)
Quotes are at least 15-min delayed:2024/12/26 13:59 EST
Last
 1.52
-0.05 (-3.18%)
Day High 
1.95 
Prev. Close
1.57 
1-M High
1.85 
Volume 
1.50M 
Bid
1.51
Ask
1.53
Day Low
1.46 
Open
1.62 
1-M Low
1.15 
Market Cap 
18.99M 
Currency USD 
P/E 0.33 
%Yield -- 
10-SMA 1.4 
20-SMA 1.33 
50-SMA 1.29 
52-W High 7.333 
52-W Low 1.1 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.11/-0.03
Enterprise Value
21.81M
Balance Sheet
Book Value Per Share
-1.56
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
SPRCSciSparc Ltd0.508+0.2868+129.66%0PE
COEPCoeptis Therapeutics Holdings0.2099+0.0679+47.82%-- 
TNXPTonix Pharmaceuticals Holding Corp.0.37-0.0153-3.97%-- 
CEROCERo Therapeutics Holdings0.06025-0.00205-3.29%-- 
GERNGeron Corp3.325-0.015-0.45%-- 
Quotes are at least 15-min delayed:2024/12/26 13:59 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.